CytomX Therapeutics financials
$2.75+2.23%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M | $10.3M | $663.0K | $6.0M | $18.7M | $50.9M | $38.1M | $33.4M | $25.1M | $41.5M | $26.6M | $26.4M |
| Gross profit | $1.4M | $10.3M | $663.0K | $6.0M | $18.7M | $50.9M | $38.1M | $33.4M | $25.1M | $41.5M | $26.6M | $26.4M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$23.8M | -$19.7M | -$27.9M | -$15.8M | -$1.3M | $22.6M | $17.7M | $4.1M | -$8.5M | $11.7M | -$606.0K | $3.1M |
| Net income | -$20.7M | -$18.2M | -$29.5M | -$14.2M | -$154.0K | $23.5M | $18.9M | $5.7M | -$6.5M | $13.8M | $837.0K | $3.0M |
| Net margin | −1457.4% | −177.9% | −4451.3% | −238.6% | −0.8% | 46.2% | 49.6% | 17.2% | −26.0% | 33.3% | 3.1% | 11.3% |
| Diluted EPS | $-0.09 | $-0.10 | $-0.17 | $-0.09 | $0.00 | $0.27 | $0.22 | $0.07 | $-0.08 | $0.17 | $0.01 | $0.04 |
| EBITDA | -$23.7M | -$19.4M | -$27.4M | -$15.6M | -$939.0K | $23.0M | $18.1M | $4.5M | -$8.0M | $12.1M | -$120.0K | $3.6M |
| Operating cash flow | -$18.1M | -$25.5M | -$23.2M | -$15.5M | -$15.8M | -$21.0M | -$19.9M | -$20.7M | -$19.5M | -$26.0M | -$22.0M | -$18.2M |
| Free cash flow | -$18.1M | -$25.5M | -$23.4M | -$15.7M | -$15.8M | -$21.2M | -$20.0M | -$20.7M | -$19.6M | -$26.2M | -$22.2M | -$18.3M |
| Diluted shares | 218.9M | 177.3M | 170.5M | 165.0M | 129.1M | 87.2M | 86.3M | 85.2M | 84.9M | 82.6M | 81.5M | 81.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $17.2M | $28.8M | $12.7M | $34.2M | $49.0M | $47.6M |
| Short-term investments | $313.1M | $317.9M | $124.4M | $109.4M | $109.0M | $32.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $381.2M | $359.4M | $151.6M | $158.3M | $175.1M | $98.5M |
| Total liabilities | $79.2M | $39.4M | $52.6M | $50.9M | $55.1M | $73.4M |
| Shareholders' equity | $302.1M | $319.9M | $99.0M | $107.4M | $119.9M | $25.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology